Tim McCarthy | LifeSci Advisors, Investor Relations |
Sergio Traversa | Chief Executive Officer |
Maged Shenouda | Chief Financial Officer |
Andrew Tsai | Jefferies |
Andrea Tan | Goldman Sachs |
Yatin Suneja | Guggenheim Partners |
Marc Goodman | SVB Leerink |
Vamil Divan | Mizuho Securities |
Matt Hershenhorn | Oppenheimer |
Ladies and gentlemen, thank you for standing by. And welcome to the Relmada Therapeutics, Inc.
First Quarter 2022 Earnings Call.
During the presentation all participants will be in listen-only mode. Afterwards, we will conduct a question-and-answer session.